Distinct temporal characteristics of circulating alveolar epithelial and endothelial injury markers in ARDS with COVID-19: a preliminary retrospective report

Kentaro Tojo[1], Natsuhiro Yamamoto[1], Takahiro Mihara[2], Miyou Abe[1], Takahisa Goto[1]

[1] *Department of Anesthesiology and Critical Care Medicine, Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan*

[2] *Department of Health Data Science, Yokohama City University Graduate School of Data Science, Yokohama, Kanagawa, Japan*

Correspondence to: Kentaro Tojo, Department of Anesthesiology and Critical Care Medicine, Yokohama City University School of Medicine, 3-9, Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan

e-mail: ktojo-cib@umin.net

Fax: +81-45-787-2916; Tel: +81-45-787-2918

Background

In the most severe cases, Coronavirus disease (COVID-19) leads to acute respiratory

distress syndrome (ARDS) that is characterized by alveolar epithelial and endothelial

injuries [1,2]. Evaluating the temporal changes of established alveolar tissue injury

markers[3] can provide insights regarding the time course and specific contribution of

alveolar epithelial and of endothelial injury to the pathogenesis of COVID-19 ARDS.

Recently, Spadaro et al. have reported that COVID-19 ARDS is characterized by the

increases of circulating endothelial injury markers[4]. However, the detailed temporal

characteristics of changes in these markers are still not clear. In this preliminary study,

we investigated the levels of a circulating alveolar epithelial injury marker; soluble

receptor for advanced glycation end-products (sRAGE), an endothelial injury marker;

angiopoietin-2 (ANG-2), and an alveolar barrier permeability indicator; surfactant

protein D (SP-D) in serum from COVID-19 patients with or without ARDS.

Methods

The patients diagnosed as COVID-19 by real-time polymerase chain reaction and

admitted to Yokohama City University Hospital from January to August 2020 were

included in this retrospective observational study (ethics reference number:

B200700100). Concentrations of sRAGE, ANG-2, and SP-D in the residual serum

samples were measured using enzyme-linked immunosorbent assay kits (human RAGE:

DY1145, human ANG-2: DY623, human SP-D: DY1920, R&D systems, MN, USA).

We compared the concentrations of these markers on the first or second hospital day

between ARDS and non-ARDS patients. Moreover, we analyzed temporal changes of

these markers during the first eight hospital days in ARDS patients.

The data between ARDS and non-ARDS patients were compared with the

Mann-Whitney U test. Temporal changes of the markers were analyzed with Friedman

test and post-hoc Dunn's test. The peak day of the each of the markers were analyzed

with Kruskal-Wallis test and post-hoc Dunn's test. All statistical analyses were

performed using Prism 9.0 software (Graphpad Software, CA, USA). Statistical

significance level was set at $P < 0.05$.

Results

Eleven ARDS and ten non-ARDS patients, all with COVID-19, were included in the

study. Patient characteristics are shown in Table 1. The diagnosis of ARDS was made

on the first or second hospital day. The initial serum levels of sRAGE and SP-D were

significantly higher in the ARDS group than in the non-ARDS group, however the

ANG-2 level was not (Table.1).

Analysis of the temporal changes of these markers in ten ARDS patients excluding one

patient with missing data revealed that serum sRAGE level peaked just after admission,

and it gradually decreased with hospital days (Fig.1). In contrast, serum ANG-2 and

SP-D did not significantly decrease during first eight hospital days and the peak timings

of these markers were during a later disease stage (Fig.1).

Discussion

The present study indicates that alveolar epithelial injury occurring at the very early

disease stage, which is indicated by the increase in sRAGE level, is a hallmark of

COVID-19 ARDS pathogenesis. On the other hand, levels of ANG-2 peaked at later

time points, suggesting that the endothelial injury continue to exacerbate for several

days after admission. Moreover, the trajectory of ANG-2 level, rather than of sRAGE

level, was parallel with the trajectory of SP-D, an indicator of alveolar barrier

permeability. These data suggest that the endothelial injury contribute to the

exacerbation of the alveolar barrier disruption during the later disease stage.

The difference in the peak timing of epithelial and endothelial injury markers suggests the distinct mechanisms for injury to each type of cell. A hypothesis generated from our results is that the initial alveolar epithelial injury might be a trigger of the subsequent endothelial injury. To obtain insights into the pathogenesis of alveolar tissue injury during COVID-19, further studies are warranted.

List of abbreviations

ARDS: acute respiratory distress syndrome; COVID-19: coronavirus disease; sRAGE: soluble receptor for advanced glycation end-products; ANG-2: angiopoietin-2; SP-D: surfactant protein D; SARS-CoV-2: severe acute respiratory syndrome coronavirus-2

Declarations:

Ethics approval and consent to participate:

The study protocol was reviewed and approved by the institutional review board of

Yokohama City University Hospital (approval number: B200700100). The need for

informed consent was waived by the institutional review boards because of the

retrospective observational design of the study.

Consent for publication:

Not applicable.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the

corresponding author on reasonable request.

Competing interests

The authors have disclosed that they do not have any potential competing interest.

Funding:

The authors have declared no specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Authors' contributions:

KT conducted the study, performed ELISA, analysed data, and wrote the manuscript. NY performed ELISA and reviewed the manuscript. TM supervised statistical data analysis and reviewed the manuscript. MA collected patients' clinical data and reviewed the manuscript. TG supervised the study and reviewed the manuscript

Acknowledgements

The authors wish to thank Department of Emergency Medicine (Prof. Ichiro Takeuchi), Department of Microbiology (Prof. Akihide Ryo), and Yokohama City University Center for Novel and Exploratory Clinical Trials for collecting and providing the blood samples.

References

1. Polak SB, Gool ICV, Cohen D, Thüsen JH von der, Paassen J van. A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. Modern Pathol. 2020;33:2128–38.

2. Deshmukh V, Motwani R, Kumar A, Kumari C, Raza K. Histopathological observations in COVID-19: a systematic review. J Clin Pathol. 2020;jclinpath-2020-206995.

3. Zee P van der, Rietdijk W, Somhorst P, Endeman H, Gommers D. A systematic review of biomarkers multivariately associated with acute respiratory distress syndrome development and mortality. Crit Care. 2020;24:243.

4. Spadaro S, Fogagnolo A, Campo G, Zucchetti O, Verri M, Ottaviani I, et al. Markers of endothelial and epithelial pulmonary injury in mechanically ventilated COVID-19 ICU patients. Crit Care. 2021;25:74.

Table.1

	non-ARDS (n=10)	ARDS (n=11)	p-Value
Age, median (IQR), years	57 (30-72)	69 (64-76)	0.2428
Males/Females	8/2	10/1	0.5865
APACHE2 score	7 (4.75-9.75)	10 (9.00-14.00)	*0.0204
P/F ratio at admission, median (IQR)	395 (304-454)	155 (108-203)	*<0.0001
Mechanical ventilation use	0	11	*<0.0001
Laboratory data on admission			
WBC count	4600 (2525-7925)	7000 (5800-9600)	0.1567
Neutrophil Count	2258 (1268-5416)	5628 (4292-7350)	*0.0430
Lymphocyte count	1003 (674-1475)	643 (342-788)	*0.0048
Platelet count	186 (86-317)	220 (176-287)	0.4262
D-dimer	0.67 (0.00-1.04)	1.35 (0.65-2.52)	*0.0404
CRP	0.98 (0.28-2.06)	14.62 (9.09-16.89)	*<0.0001

Creatinine	0.75 (0.63-0.87)	0.75 (0.59-0.89)	>0.9999
Total bilirubin	0.55 (0.40-0.78)	0.60 (0.50-1.00)	0.5661
Alveolar tissue injury marker levels on admission			
sRAGE	896 (402-1718)	2328 (1404-4982)	*0.0079
ANG-2	334(65-781)	699 (405-2201)	0.1321
SP-D	2407 (772-3833)	16596 (6733-21397)	*0.0062

Figure Legends

Figure.1

Temporal changes of (A) sRAGE, (B) ANG-2, and (C) SP-D levels in ARDS patients

with COVID-19 for 8 days starting from admission. In cases where values for every

2-days were available, then an average of the values was used; where only a single day

value was available, then that was used. (D) The peak day of each of the alveolar tissue

injury markers. Data were presented as median ± IQR.